D
evelopment of eff ective vaccines for the immunotherapy of cancer or persistent infectious disease will require the reactivation of a suboptimal immune response; in the case of cancer immuno therapy this oft en involves breaking immunologic tolerance to selfantigens expressed by the tumor cells. Dendritic cells (DCs) are the most potent antigen-presenting cells of the immune system, and much eff ort has therefore been devoted to methods for delivering appropriate antigen to DCs to induce immunization. Initial DC therapies tested in clinical trials used autologous DCs cultured in the laboratory, loaded with antigen, and then re-injected. 1 However, more cost-eff ective and effi cient protocols will involve direct delivery of antigens to DCs in vivo. 2 Targeting of antigens to DCs can be achieved by linking antigens to antibodies that recognize DC surface molecules (e.g., Bonifaz et al.
3 ) or by targeting viral vectors to DCs so that they then express antigens within the antigen-presenting cell. DCs residing in the skin and lymph nodes constitute the natural detection system for external pathogens and are thus relevant for vaccination. Viral vector targeting to DCs can potentially avoid antigen expression in other tissues, and DCs may recognize the viral vectors as pathogens and become activated, increasing the potency of immunization. Adenoviral vectors are potent immunogens, and it has recently proved possible to engineer adenovirus serotype 5 to improve DC specifi city and maintain immunogenicity. 4 Targeting of enveloped viruses-for example, using single-chain antibodies fused to murine leukemia virus envelope-has oft en resulted in relatively ineffi cient infection because the function of the chimeric envelope protein was compromised to some extent (e.g., Martin et al. 5 ). As an alternative solution to this problem, binding-defi cient but fusion-competent mutants were isolated from Sindbis and measles viruses and used to retarget binding without affecting the effi ciency of fusion. 6, 7 In these viruses the binding and fusion functions could be separated because they reside on diff erent envelope glycoproteins. Th e Sindbis virus envelope has also been used for retargeting lentiviral vectors (lentivectors). 8 Lentivectors are attractive vaccine vector candidates because they can transduce DCs in vivo without interfering with their function and then induce both cellular and humoral immune responses. [9] [10] [11] In a recent article, Yang and collaborators presented an elegant piece of work in which they achieved high targeting specifi city in vivo using a lentivectorbased vaccine. 12 Instead of trying to add a new module to the glycoprotein so as to target the vector, they decided to take advantage of the in vivo tropism of Sindbis virus, which naturally shows preference for DCs. Th ey further restricted infection by inactivating its binding to broadly expressed heparan sulfate molecules. Th is strategy enabled them to show infection of DCs in culture via DC-SIGN, the other natural receptor of Sindbis virus, which is expressed mainly by DCs. Interestingly, this modifi ed glycoprotein works equally well with mouse and human DC-SIGN molecules, making it an interesting candidate for human therapeutic applications. Th e in vivo studies in mice showed infection of DCs, with substantially fewer offtarget transduction events than with the more commonly used vesicular stomatitis virus G (VSV-G)-pseudotyped lentivectors. Despite reducing the number of in vivo-infected cells, this protocol still resulted in strong immunization against the model antigen ovalbumin, with the induction of both specifi c CD8 + T cells and an antibody response. In this respect, the authors' results resemble those from our group using a specifi c promoter to target lentivector-driven antigen expression to DCs in vivo. 13 From a functional point of view, the surface-targeted in vivo vaccination was strong enough to protect mice against challenge with a tumor expressing ovalbumin, and it also proved effi cient in tumor-therapy experiments.
Th ese results are highly encouraging for the future of lentivector-based vaccination strategies. However, before they can be used with patients for whom alternative therapies exist, there are safety considerations that must be tackled, such as the possibility of insertional mutagenesis. Th e reduction in in vivo-transduced cells that can be achieved by effi cient targeting © The American Society of Gene Therapy commentary of DCs is an important step; however, the in vivo tropism of the targeted Sindbis virus must be further assessed with more sensitive methods than the luciferasebased system used in the present study. It is possible that the background infection of cells lacking DC-SIGN still shown by this system may be improved by further mutagenesis. Furthermore, persistence of transduced DCs or other antigen-presenting cells following vector integration may result in prolonged antigen presentation, the consequences of which are not yet fully understood. Th e ability of DCs to capture viruses via DC-SIGN and transmit them to other cells must also be evaluated in this system. In the case of HIV, this mechanism results in viral spreading far from the site of initial infection.
14 Despite these technical issues, Yang and collaborators provide a proof-ofprinciple study of lentivector targeting to DCs, which can lead to improved human vaccination. A strength of their strategy may be that, compared with other lentiviral pseudotypes that have been tested in mice, the targeting via DC-SIGN results in both antigen presentation and concomitant DC activation, demonstrated in mouse DC cultures. We have reported that VSV-G-pseudotyped lentivectors do not activate such mouse DCs unless an intracellular activator of the p38 MAP kinase pathway is coexpressed with the antigen. 15 Th e reason for the diff erence between Sindbis-and VSV-G-pseudotyped lentivectors in the induction of DC maturation is unknown; it may be hypothesized that attachment of Sindbis glycoproteins to DC-SIGN provides DCs with the maturation signals they require. Th is could allow initiation of a strong immune response despite low transduction effi ciency.
